Vincerx Pharma (NASDAQ: VINC)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.790 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Vincerx Pharma (NASDAQ: VINC) through any online brokerage.
Other companies in Vincerx Pharma’s space includes: Virios Therapeutics (NASDAQ:VIRI), Synaptogenix (NASDAQ:SNPX), Celyad Oncology (NASDAQ:CYAD), T2 Biosystems (NASDAQ:TTOO) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Chardan Capital on Friday, May 13, 2022. The analyst firm set a price target for 11.00 expecting VINC to rise to within 12 months (a possible 521.47% upside). 10 analyst firms have reported ratings in the last year.
The stock price for Vincerx Pharma (NASDAQ: VINC) is $1.77 last updated May 20, 2022, 8:00 PM UTC.
There are no upcoming dividends for Vincerx Pharma.
Vincerx Pharma’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Vincerx Pharma.
Vincerx Pharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.